Almost half of 9 and 10-year-olds get HPV vaccination at first opportunity This spring, more than 800,000 young people received an invitation to be vaccinated against HPV, the human papillomavirus.
Insufficient knowledge to protect the health of the Dutch population from climate change The climate is changing. This process is already affecting the health of people in the Netherlands. As such, it is important to take immediate action to prepare the Netherlands and its population for climate change and to reduce the effects on health
RIVM expands HPV vaccination programme: girls and boys protected from six types of cancer with one vaccine Now not only girls, but also boys will have the opportunity to protect themselves from cancer caused by HPV.
Better monitoring of RSV thanks to new European project RIVM and Nivel contribute to building a European RSV monitoring network. Through the network, European health institutions and laboratories will exchange data on the spread of RSV. This will help us to better monitor the virus.
RIVM magazine special edition on Climate Change and Health The RIVM Magazine special edition on Climate change and Health showcases the scope of RIVM’s work on this topic.
State Secretary Blokhuis: boys will also be vaccinated against HPV virus The vaccine against the HPV human papillomavirus virus will also become available for boys.
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Vaccination rate again drops slightly, HPV vaccination rate drops considerably The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.
RIVM and Olive Foundation open trading to mark the European Cervical Cancer Prevention Week January 20th, the Olive Foundation and RIVM opened AEX trading day in Amsterdam on the occasion of the 9th European Cervical Cancer Prevention Week.
The National Immunisation Programme in the Netherlands 2013 - 2014 Every year, RIVM provides an overview of surveillance and developments in the National Immunisation Programme (NIP).